Skip to content
Sign in
Corporate VCBacked 1 network startup

bioMérieux

bioMérieux, French in-vitro diagnostics group, investing in MedTech and life sciences, including its Allergen Alert intrapreneurship spin-off.

Marcy-l'Étoile, France
Ticket
—Not published
Assets under management
—
Founded
—
Stages
—
Network startups backed
1
Co-investors
2most often with Bpifrance

How they invest

Strategic investments in MedTech and biotech, with Allergen Alert (food allergen detection) born from its intrapreneurship programme. As a diagnostics leader (general knowledge), strategic fit centres on diagnostics, microbiology and food safety testing.

Stage and ticket

Not specified; Allergen Alert seed is the network deal.

Geography

Not specified; HQ France (Marcy-l'Étoile).

What makes them say yes

  • Diagnostic or detection technology adjacent to bioMérieux's lines
  • Clinical or industrial validation data
  • Path to commercial partnership/distribution

Red flags

  • No diagnostics/detection angle
  • Pure software without lab or clinical validation (inference)

Sectors

  • MedTech & devices
  • Biotech & life sciences

Stages

Not published

Geographies

Not published

How to approach

Approach via bioMérieux corporate development or the Allergen Alert team (network peer). Pitch partnership first, investment second.

Portfolio

1 network startup · no other company

One network deal: Allergen Alert seed (2025) with Bpifrance and Demeter, a corporate spin-off in food safety detection.

Gaps in the portfolio

  • No network clinical diagnostics company
  • No network sensing / e-nose company

Network startups

  • Allergen AlertSWC 2026 Finalist

    France · Agri & FoodTech

    bioMérieux spin-off miniaturising allergen testing into a pocket lab; strong backers, but still pre-product.

Network startups that fit

4 analysed

Melbourne start-up developing an at-home urine test with machine learning to screen for endometriosis.

Urine-based endometriosis diagnostic in development: in-vitro diagnostics in an underserved indication. R&D stage with no published clinical study, so a partnership-first approach fits.

40%confidence

Evidence from the records

  • “Women's health diagnostics (endometriosis)”
  • “urine endometriosis test in development”
Intro path
Allergen Alert (bioMérieux spin-off, network peer)
First step
Share the assay validation plan with bioMérieux corporate development.

Mahidol University spin-off digitising smell with an AI electronic nose, deployed for quality control at Ajinomoto, Double A and PTT.

Thai sensory-AI e-nose deployed at Ajinomoto and PTT: detection technology relevant to food and industrial quality testing, adjacent to Allergen Alert.

35%confidence

Evidence from the records

  • “Sensory AI / electronic nose”
  • “E-nose deployed at Ajinomoto, Double A and PTT”
Intro path
Allergen Alert (food safety peer)
First step
Propose a joint food-safety detection pilot.

Tufts spin-off with an IRB-approved ingestible capsule that samples small-intestine microbiome and contents non-invasively.

Ingestible small-intestine sampling capsule, NSR/IRB-approved for human use: sampling feeds microbiology diagnostics. Pre-seed prototype.

35%confidence

Evidence from the records

  • “Ingestible small intestine sampling capsule”
  • “NSR/IRB approved for human use”
First step
Pitch sample-to-diagnostic workflow integration.

Smartphone eyelid-photo AI that screens for anemia in seconds without a blood draw, aimed at low-resource care.

Smartphone-photo anemia detection: non-invasive screening, but software-only versus bioMérieux's IVD lines.

20%confidence

Evidence from the records

  • “AI anemia detection”
  • “MIT Solve 2024 selection”
First step
Position as a triage layer feeding lab confirmation.

Analyst reading of 21 Nov 2026, from the public record of the network. Method: analyst-ai.

Co-investors

Most often with Bpifrance and Demeter Investment Managers

Sources

  1. 1biomerieux.com/corp/en/who-we-are/company-news/biomerieux-invests-allergen

Profile compiled from public sources. Unknown fields are left empty rather than estimated.